These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16899626)

  • 1. Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo.
    Li L; Lin X; Shoemaker AR; Albert DH; Fesik SW; Shen Y
    Clin Cancer Res; 2006 Aug; 12(15):4747-54. PubMed ID: 16899626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.
    Mathieu V; De Nève N; Le Mercier M; Dewelle J; Gaussin JF; Dehoux M; Kiss R; Lefranc F
    Neoplasia; 2008 Dec; 10(12):1383-92. PubMed ID: 19048117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
    Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy.
    Kun Z; Yuling Y; Dongchun W; Bingbing X; Xiaoli L; Bin X
    Technol Cancer Res Treat; 2016 Dec; 15(6):NP95-NP104. PubMed ID: 26647409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
    Palma JP; Wang YC; Rodriguez LE; Montgomery D; Ellis PA; Bukofzer G; Niquette A; Liu X; Shi Y; Lasko L; Zhu GD; Penning TD; Giranda VL; Rosenberg SH; Frost DJ; Donawho CK
    Clin Cancer Res; 2009 Dec; 15(23):7277-90. PubMed ID: 19934293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.
    Yeo EJ; Chun YS; Cho YS; Kim J; Lee JC; Kim MS; Park JW
    J Natl Cancer Inst; 2003 Apr; 95(7):516-25. PubMed ID: 12671019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
    Miknyoczki S; Chang H; Grobelny J; Pritchard S; Worrell C; McGann N; Ator M; Husten J; Deibold J; Hudkins R; Zulli A; Parchment R; Ruggeri B
    Mol Cancer Ther; 2007 Aug; 6(8):2290-302. PubMed ID: 17699724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
    Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells.
    Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Sonawane V; Rathos MJ; Kumar S; Joshi KS
    BMC Cancer; 2011 Aug; 11():338. PubMed ID: 21819554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
    Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
    Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
    Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
    Zhou Q; Guo P; Gallo JM
    Clin Cancer Res; 2008 Mar; 14(5):1540-9. PubMed ID: 18316579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
    Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
    Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.
    Cejka D; Preusser M; Woehrer A; Sieghart W; Strommer S; Werzowa J; Fuereder T; Wacheck V
    Cancer Biol Ther; 2008 Sep; 7(9):1377-85. PubMed ID: 18708754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1alpha suppression.
    Kim SH; Kim KW; Jeong JW
    Oncol Rep; 2007 Apr; 17(4):793-7. PubMed ID: 17342317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
    Donawho CK; Luo Y; Luo Y; Penning TD; Bauch JL; Bouska JJ; Bontcheva-Diaz VD; Cox BF; DeWeese TL; Dillehay LE; Ferguson DC; Ghoreishi-Haack NS; Grimm DR; Guan R; Han EK; Holley-Shanks RR; Hristov B; Idler KB; Jarvis K; Johnson EF; Kleinberg LR; Klinghofer V; Lasko LM; Liu X; Marsh KC; McGonigal TP; Meulbroek JA; Olson AM; Palma JP; Rodriguez LE; Shi Y; Stavropoulos JA; Tsurutani AC; Zhu GD; Rosenberg SH; Giranda VL; Frost DJ
    Clin Cancer Res; 2007 May; 13(9):2728-37. PubMed ID: 17473206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells.
    Jaiswal AS; Banerjee S; Panda H; Bulkin CD; Izumi T; Sarkar FH; Ostrov DA; Narayan S
    Mol Cancer Res; 2009 Dec; 7(12):1973-83. PubMed ID: 19996303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.